Myeloma News

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the use of minimal residual disease testing to determine cessation of therapy in patients with multiple myeloma.

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the role of quadruplet induction regimens for transplant-ineligible patients with multiple myeloma.

CHICAGO — In this video, Adam Cohen, MD, discussed findings from the DREAMM-7 and DREAMM-8 trials presented at ASCO Annual Meeting.

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about a study in older patients with relapsed/refractory multiple myeloma.

CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.

CHICAGO — In this video, Henry Chi Hang Fung, MD, FACP, FRCPE, discussed findings assessing the treatment of patients with multiple myeloma who are ineligible for transplant.

CHICAGO — Isatuximab combined with a standard first-line treatment regimen significantly reduced the risk for disease progression and death in certain older individuals with multiple myeloma, results from a randomized phase 3 study showed.

CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting.

CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with standard care for patients with relapsed or refractory multiple myeloma, according to data presented at ASCO Annual Meeting.